Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 23, 2002

View Archived Issues

LY-451395 enters the brain following multiple oral doses in man

Favorable pharmacokinetic profile described for new camptothecin analogue DRF-1042

Escalating oral and i.v. doses of sabiporide tested in humans for safety and PK/PD profile

New data on natalizumab presented at ACTRI/ECTRI conference

Zenapax may improve the therapeutic effect of interferon in multiple sclerosis

Quetiapine found to improve cognitive function in first-episode psychosis

No antiplatelet effects found for a supratherapeutic dose of valdecoxib in healthy subjects

Potential reported for RWJ-67657 in the management of sepsis and cytokine-mediated disorders

Acyline is safe and decreases serum gonadotropin and testosterone levels in humans

New data on the antiangiogenic effects of endostatin against advanced solid tumors

Cilomilast proven effective in improving lung function of smoking and nonsmoking COPD patients

Beneficial effects on chronic lung rejection reported for switching from ciclosporin to tacrolimus

Cozaar reduces the risk of ESRD in patients with type 2 diabetes, nephropathy and hypertension

Global collaboration signed for potential breakthrough diabetes therapy

Genmab's HuMax-CD4 enters phase IIb trial in psoriasis

Endovasc spin-off company will develop Liprostin

Access Oncology obtains rights to develop and market antitumor alkylphosphocholine

Hybridon and Aegera collaborate to develop antisense drug targeting XIAP gene

5-HT6 ligands claimed in the patent literature by Wyeth

Urotensin-II receptor antagonists and potential uses described in recent patent

Novel CRF1 antagonists identified at Bristol-Myers Squibb

Synthesis, activity and use of glycine uptake inhibitors reported

Recent patent covers new human PPAR activators discovered at GSK

GSK designs new series of antiangiogenic agents

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.